Literature DB >> 16574730

A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.

R C Graham1, R A C Hughes.   

Abstract

A new peripheral neuropathy activities measure, the Overall Neuropathy Limitations Scale (ONLS), was derived by modifying the Overall Disability Sum Score (ODSS) slightly. Its inter-rater reliability was found to be high and its correlation with the ODSS (r = 0.97), 36-item Short Form Questionnaire Physical Component Summary Score, and participation and impairment measures was significant. Acceptable responsiveness (standardised response mean 0.76) was shown by the ONLS. The results obtained from the questionnaire agreed closely with those obtained from observation of the tasks on the ONLS, but were not equivalent. The simplicity of the ODSS is shared by the ONLS, but the ONLS has better content validity and less ceiling effect, which may make it more useful for clinical practice and research.

Entities:  

Mesh：

Year:  2006        PMID： 16574730      PMCID： PMC2077620          DOI： 10.1136/jnnp.2005.081547

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  9 in total

1.  Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome.

Authors:  R P Kleyweg; F G van der Meché; P I Schmitz
Journal:  Muscle Nerve       Date:  1991-11       Impact factor: 3.217

2.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

3.  The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis.

Authors:  B Sharrack; R A Hughes
Journal:  Mult Scler       Date:  1999-08       Impact factor: 6.312

4.  Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies.

Authors:  Ingemar S J Merkies; Paul I M Schmitz; Frans G A Van Der Meché; Johnny P A Samijn; Pieter A Van Doorn
Journal:  Muscle Nerve       Date:  2002-03       Impact factor: 3.217

5.  Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.

Authors:  I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

6.  Quality of life complements traditional outcome measures in immune-mediated polyneuropathies.

Authors:  I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn
Journal:  Neurology       Date:  2002-07-09       Impact factor: 9.910

7.  A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy.

Authors:  R A C Hughes; T Umapathi; I A Gray; N A Gregson; M Noori; A S Pannala; A Proteggente; A V Swan
Journal:  Brain       Date:  2004-06-16       Impact factor: 13.501

8.  Comparison between impairment and disability scales in immune-mediated polyneuropathies.

Authors:  Ingemar S J Merkies; Paul I M Schmitz; Frans G A Van Der Meché; Pieter A Van Doorn
Journal:  Muscle Nerve       Date:  2003-07       Impact factor: 3.217

9.  Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).

Authors:  J C Hobart; A Riazi; D L Lamping; R Fitzpatrick; A J Thompson
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910
  9 in total
  67 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Clinical outcomes of patients with lumbar disc herniation, selected for one-level open-discectomy and microdiscectomy.

Authors:  Kotryna Veresciagina; Bronius Spakauskas; Kazys Vytautas Ambrozaitis
Journal:  Eur Spine J       Date:  2010-05-26       Impact factor: 3.134

Review 3.  Drug therapy for chronic idiopathic axonal polyneuropathy.

Authors:  Janna Warendorf; Alexander Fje Vrancken; Ivo N van Schaik; Richard Ac Hughes; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

4.  Polyneuropathy dysfunction scores.

Authors:  P J Dyck; P C O'Brien
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05-18       Impact factor: 10.154

Review 5.  Progress in peripheral nerve disease research in the last two years.

Authors:  Matthew Evans; Hadi Manji
Journal:  J Neurol       Date:  2013-10-25       Impact factor: 4.849

6.  Successful treatment with rituximab of one patient with CANOMAD neuropathy.

Authors:  Emilien Delmont; P Y Jeandel; A M Hubert; L Marcq; J Boucraut; C Desnuelle
Journal:  J Neurol       Date:  2009-12-04       Impact factor: 4.849

Review 7.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard Ac Hughes; Man Mohan Mehndiratta; Yusuf A Rajabally
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

8.  Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies.

Authors:  Emilien Delmont; P Y Jeandel; C Benaïm; E Rosenthal; J G Fuzibet; C Desnuelle
Journal:  J Neurol       Date:  2011-03-25       Impact factor: 4.849

Review 9.  Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

Authors:  Anne Louise Oaklander; Michael Pt Lunn; Richard Ac Hughes; Ivo N van Schaik; Chris Frost; Colin H Chalk
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

10.  Gluten neuropathy: prevalence of neuropathic pain and the role of gluten-free diet.

Authors:  Panagiotis Zis; Ptolemaios Georgios Sarrigiannis; Dasappaiah Ganesh Rao; Marios Hadjivassiliou
Journal:  J Neurol       Date:  2018-07-21       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.